Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis — Probabli.AI
AI-powered analysis for RXRX (Recursion Pharmaceuticals, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $3.07 · Market cap: $1.6B · AI outlook: Bullish
Recursion Pharmaceuticals, Inc. (RXRX) is positioned as a growth-oriented pharmaceutical stock leveraging AI-driven technologies and robust pipelines. The recent developments in drug trials and key partnerships signal substantial upside. While regulatory challenges and profitability concerns provide bearish scenarios, the overall sentiment remains bullish based on extraordinary revenue growth…
Probabilistic 1-Year Outlook
- Bull 45% · Neutral 35% · Bear 20%
- 1-year price estimates — P10: $3 / P50: $5 / P90: $9
- Recursion Pharmaceuticals benefits from a strong revenue growth projection, positive pipeline developments, and favorable analyst sentiment. Despite some recent regulatory setbacks, the overall sentiment leans bullish…
5-Year Outlook
- Bull 60% · Neutral 25% · Bear 15%
- 5-year price estimates — P10: $4 / P50: $15 / P90: $30
SWOT Highlights
- Strength: High projected revenue growth of 31280%.
- Strength: Innovative AI partnership enhancing drug discovery.
- Risk: Negative EPS estimates indicating unprofitability.
- Risk: Regulatory risks including FDA delays.
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
4 Wall Street analysts rate RXRX a BUY with a mean price target of $7.5.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
RXRX forecast details · RXRX sentiment details · RXRX insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.